Globe Newswire (Mon, 22-Jun 2:07 PM ET)
Globe Newswire (Tue, 16-Jun 4:05 PM ET)
Globe Newswire (Thu, 11-Jun 4:17 PM ET)
Globe Newswire (Tue, 9-Jun 4:05 PM ET)
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Globe Newswire (Wed, 13-May 4:05 PM ET)
iMDx to Release First Quarter 2026 Results on May 13, 2026
Globe Newswire (Wed, 6-May 4:05 PM ET)
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
Globe Newswire (Tue, 14-Apr 8:00 AM ET)
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
Globe Newswire (Thu, 26-Mar 4:05 PM ET)
Market Chameleon (Fri, 20-Mar 6:13 AM ET)
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics trades on the NASDAQ stock market under the symbol IMDX.
As of June 24, 2026, IMDX stock price climbed to $5.53 with 83,482 million shares trading.
IMDX has a beta of 2.31, meaning it tends to be more sensitive to market movements. IMDX has a correlation of 0.09 to the broad based SPY ETF.
IMDX has a market cap of $178.56 million. This is considered a Micro Cap stock.
Last quarter Insight Molecular Diagnostics reported $32,000 in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-195,500 and missed earnings estimates by -$.02.
The top ETF exchange traded funds that IMDX belongs to (by Net Assets): VTI, VXF, IWC.
IMDX has outperformed the market in the last year with a return of +51.1%, while the SPY ETF gained +24.2%. In the last 3 month period, IMDX beat the market returning +38.3%, while SPY returned +12.9%. However, in the most recent 2 weeks IMDX has underperformed the stock market by returning -5.5%, while SPY returned +0.4%.
IMDX support price is $4.94 and resistance is $5.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMDX shares will trade within this expected range on the day.
